Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cellsThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.
Author(s) -
Francesca Spinella,
Valentina Caprara,
Emirena Garrafa,
Valeriana Di Castro,
Laura Rosanò,
Pier Giorgio Natali,
Anna Bagnato
Publication year - 2010
Publication title -
canadian journal of physiology and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.559
H-Index - 84
eISSN - 1205-7541
pISSN - 0008-4212
DOI - 10.1139/y10-050
Subject(s) - lymphangiogenesis , lymphatic system , lymphatic vessel , matrix metalloproteinase , endothelin receptor , lymphatic endothelium , cancer research , endothelins , vascular endothelial growth factor c , microbiology and biotechnology , metalloproteinase , receptor , biology , endothelin 1 , extracellular matrix , immunology , pathology , medicine , cancer , vascular endothelial growth factor , vascular endothelial growth factor a , metastasis , biochemistry , vegf receptors
The molecular mechanisms involved in lymphangiogenesis were unknown until recently. We previously demonstrated that the endothelin-1 (ET-1) axis stimulates lymphatic endothelial cells (LEC) and lymphatic vessels to grow and invade. Here we further investigated the effect of ET-1 on lymphatic vessels and evaluated whether ET-1 actions result in the functional activation of lymphangiogenesis. Using highly purified human LEC, characterized for the expression of ET-1 axis members by quantitative real-time PCR, we found that the endothelin B receptor (ET B ), upon activation by ET-1, induced matrix-metalloproteinase activation, demonstrating that ET-1 influenced the activity of the proteolytic enzymes required for LEC invasion. Functional assays performed by using intradermal lymphangiography demonstrated that ET-1 promoted the formation of lymphatic vessels and that these vessels were capable of lymphatic flow. ET B blockade with the specific antagonist BQ788 inhibited matrix-metalloproteinase activation and dye transport within the lymphatic vessels, demonstrating that ET B is involved in the regulation of the growth of and in the formation of functional vessels upon activation by ET-1. Our results suggest that ET-1 is a lymphangiogenic mediator and that targeting pharmacologically ET B may be therapeutically exploited in a variety of diseases, including cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom